The US FDA recently approved the Boehringer Ingelheim and Lilly’s combination drug Glyxambi as a dietary supplement to improve glycemic control in adults with Type 2 Diabetes (T2D) who can be treated with the drug’s active ingredients, ISNA reported.
“Today’s medical community recognizes the need to treat T2D from multiple fronts to help patients improve glycemic control,” said Paul Fonteyne, Boehringer Ingelheim president and CEO.
Half of the people with T2D do not achieve recommended blood sugar control, making new treatment options more important than ever, said Mike Mason, vice president of Lilly Diabetes. “The approval of Glyxambi gives physicians and patients a first-in-class prescription medicine to help manage this condition.”
